ICYMI—In people with type 2 diabetes at increased cardiovascular risk, the cardiovascular safety of orforglipron was confirmed by demonstrating non-inferiority to insulin glargine for MACE-4. Phase 3 ACHIEVE-4 trial supports orforglipron as potential once-daily, oral treatment option. spkl.io/60137X6Hf
Thread
Nenhum Voo ainda